




12 November 2021 - virtual
22, 23 November 2021 – onsite, live streaming
26 November 2021 - virtual

Scientific Coordinators: V. Valentini, M.A. Gambacorta, L. Indovina
Honorary Presidents: C.A. Perez, N. Cellini

Struttura



12 November 2021
(VIRTUAL)

16.00-16.05 Opening: course aims and modalities

V.Valentini, M.A.Gambacorta

16.05-16.15	What is considered compliance in the 20's?	M.A. Gambacorta
-------------	--	-----------------

Opening lecture (recorded)

16.15-16.40	Omics sciences and compliance to radiotherapy: is there a link?	A. Chalmers
-------------	---	-------------

Session 1 (live)

Metrics: Which compliance to be measured?

16.40-16.55	...in radiotherapy randomized trials. The clinical perspective	P. Hoskin
16.55-17.10	...in radiotherapy randomized trials. The dosimetric perspective	D. Verellen
17.10-17.25	...in technical innovations. The clinical perspective	B. Jereczek
17.25-17.40	...in technical innovations. The dosimetric perspective	G.J. Meijer

17.40-17.55 Question time

17.55-18.10 Break

Laboratory 1 (live)

18.10-18.55	PROM, PREM, App and IOT
-------------	-------------------------

22 November 2021
(ONSITE and LIVE STREAMING)

Session 2 (live)

Metrics: which compliance is important for the patient undergoing radiotherapy?

09.00-09.15	Treatment compliance: patient' vs clinicians' perspectives	P. Hoskin
09.15-09.30	Treatment compliance: the psychological dimension in adults	L. Dinapoli
09.30-09.45	Treatment compliance: priorities of care in the elderly	G.F. Colloca
09.45-10.00	Treatment compliance: the relational dimension in paediatrics	E. Marconi

10.00-10.15 Question time

10.15-10.30 Break

Session 3 (live)

Actions: How to prevent and recover no-compliance?

10.30-10.45	Recommendations for non-compliance in radiotherapy treatments	K. Haustermans
10.45-11.00	Recommendations for non-compliance in chemoradiotherapy treatments	E. Fokas
11.00-11.15	Innovation: AI and error prevention in RT	D. Verellen
11.15-11.30	Innovation: nutritional aspects and microbioma	A. Gasbarrini

11.30-11.45 Question time

Lecture 1 (live or recorded)

11.45-12.10	Image guided radiotherapy technologies and treatment compliance	U. Ricardi
-------------	---	------------

Laboratory 2 (live)

12.10-12.55	Virtual coaching during innovative oncology treatments
-------------	--

12.55-14.30 Lunch Break

Session 4 (live)

Actions: Will innovation change compliance in radiotherapy treatments?

14.30-14.45	Innovation in image guided external beam radiotherapy	G.J. Meijer
14.45-15.00	Innovation in adaptive external beam radiotherapy	S. Corradini
15.00-15.15	Innovation in interventional radiotherapy	L. Tagliaferri
15.15-15.30	Innovation in particle therapies external beam radiotherapy	A. Hoffman

15.30-15.45 Question time

15.45-16.00 Break

Lecture 2 (live or recorded)

16.00-16.25	What is considered innovation in 20's radiotherapy?	A. Kirby
-------------	---	----------

Session 5 (live)

Actions: Big Data and AI: which contribution to compliance?

16.25-16.40	Big Data and AI for compliance monitoring clinical meaning	tbd
16.40-16.55	Big Data and AI for compliance prediction	A. Dekker
16.55-17.10	Art and AI for patient's resilience	V. Valentini

17.10-17.25 Question time

Lecture 3 (live or recorded)

17.45 -18.10	Compliance to treatments using stereotactic technologies	M. Guckenberger
--------------	--	-----------------

23 November 2021
(ONSITE and LIVE STREAMING)

Lecture 4 (live or recorded)

09.00-09.25	FLASH therapy and compliance: a new era?	J. Bourhis
-------------	--	------------

Session 6 (live)

Actions: Does drug innovation change compliance in combined treatments?

09.25-09.40	Monoclonal antibodies and small molecules	E. Fokas
09.40-09.55	Immune checkpoint blockade	M. De Jong
09.55-10.10	Androgen pathway therapy	S. Arcangeli

10.10-10.25 Question time

Lecture 5 (live or recorded)

10.25-10.50	Immunotherapy and radiotherapy: efficacy, innovative fractionations and compliance	P. Lambin
-------------	--	-----------

10.50-11.05 Break

Session 7 (live)

Focus on: Prostate cancer innovation and compliance

11.05-11.25	Innovation, effectiveness and compliance in prostate cancer	M. Bolla
11.25-11.40	Constraints and toxicity in standard treatments	B. Jereczek
11.40-11.55	Constraints and toxicity in innovative treatments	N. Jornet

11.55-12.10 Question time

Session 8 (live)

Focus on: H&N cancer innovation and compliance

12.10-12.30	Innovation, effectiveness and compliance in H&N cancers	V. Grégoire
12.30-12.45	Constraints and toxicity in non conventional fractionations	P. Bonomo
12.45-13.00	Constraints and toxicity in innovative therapies combinations	R. Martinez-Monge

13.00-13.15 Question time

13.15-14.30 Lunch Break

Lecture 6 (live)

14.30-15.00 Sponsored lectures

Session 9 (live)

Focus on: Lung cancer innovation and compliance

15.00-15.20	Innovation, effectiveness and compliance in lung cancers	tbd
15.20-15.35	Constraints and toxicity in standard treatments	S. Ramella
15.35-15.50	Constraints and toxicity in innovative treatments	M. Massaccesi

15.50-16.10 Question time

Lecture 7 (live or recorded)

16.10-16.30	Compliance between innovation and clinical experience: health economics perspective	Y.Lievens
-------------	---	-----------

16.30-16.45 Closing remarks

V.Valentini, M.A.Gambacorta

26 November 2021
(VIRTUAL)

Lecture 8 (live or recorded)

15.30-15.55	Particle therapy and patient compliance	E. Troost
-------------	---	-----------

Session 10 (live)

Focus on: Breast cancer innovation and compliance

15.55-16.15	Innovation, effectiveness and compliance in breast cancer	A.Kirby
16.15-16.30	Constraints and toxicity in standard treatments	F. Marazzi
16.30-16.45	Constraints and toxicity in non standard fractionation treatments	I. Meattini

16.45-17.00 Question time

17.00-17.15 Break

Session 11 (live)

Focus on: Anal cancer innovation and compliance

17.15-17.35	Innovation, effectiveness and compliance in anal cancer	K. Haustermans
17.35-17.50	Constraints and toxicity in standard treatments	P.F. Franco
17.50-18.05	Constraints and toxicity in interventional radiotherapy treatments	G. Kovács

18.05-18.20 Question time

18.20 Closing remarks

V.Valentini, M.A.Gambacorta